Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

Maria Teresa Voso; DI MEDICINA E CHIRURGIA "A.GEMELLI" FACOLTA'; Pl Zinzani; M Tani; A Pulsoni; M Gobbi; A Perotti; S De Luca; A Fabbri; A Zaccaria; P Fattori; L Guardigni; S Ronconi; Mg Cabras; L Rigacci; A De Renzo; E Marchi; V Stefoni; M Fina; C Pellegrini; G Musuraca; E Derenzini; S Pileri; S Fanti; Pp Piccaluga; M. Baccarani

doi:10.1016/S1470-2045(08)70039-1

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

Maria Teresa Voso, DI MEDICINA E CHIRURGIA "A.GEMELLI" FACOLTA', Pl Zinzani, M Tani, A Pulsoni, M Gobbi, A Perotti, S De Luca, A Fabbri, A Zaccaria, P Fattori, L Guardigni, S Ronconi, Mg Cabras, L Rigacci, A De Renzo, E Marchi, V Stefoni, M Fina, C PellegriniG Musuraca, E Derenzini, S Pileri, S Fanti, Pp Piccaluga, M. Baccarani

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

69 Citazioni (Scopus)

Abstract

Follicular lymphoma is the most common form of lymphoma in Europe and the USA. In this prospective, single-arm, open-labelled, multicentre non-randomised phase II trial (FLUMIZ [FLUdarabine, MItoxantrone, Zevalin] trial) we aimed to assess the efficacy and safety of fludarabine and mitoxantrone plus radioimmunotherapy in untreated patients with follicular non-Hodgkin lymphoma (NHL).

Lingua originale	English
pagine (da-a)	352-358
Numero di pagine	7
Rivista	THE LANCET ONCOLOGY
Volume	9
DOI	https://doi.org/10.1016/S1470-2045(08)70039-1
Stato di pubblicazione	Pubblicato - 2008
Pubblicato esternamente	Sì

Keywords

Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Italy
Kaplan-Meier Estimate
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Male
Maximum Tolerated Dose
Middle Aged
Mitoxantrone
Neoplasm Staging
Probability
Radioimmunotherapy
Risk Assessment
Survival Analysis
Vidarabine
Yttrium Radioisotopes

Accesso al documento

10.1016/S1470-2045(08)70039-1

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Voso, M. T., FACOLTA', DI. MEDICINA. E. CHIRURGIA., Zinzani, P., Tani, M., Pulsoni, A., Gobbi, M., Perotti, A., De Luca, S., Fabbri, A., Zaccaria, A., Fattori, P., Guardigni, L., Ronconi, S., Cabras, M., Rigacci, L., De Renzo, A., Marchi, E., Stefoni, V., Fina, M., ... Baccarani, M. (2008). Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). THE LANCET ONCOLOGY, 9, 352-358. https://doi.org/10.1016/S1470-2045(08)70039-1

@article{34a824f7f9e642cd97d34b3b50a6516d,

title = "Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)",

abstract = "Follicular lymphoma is the most common form of lymphoma in Europe and the USA. In this prospective, single-arm, open-labelled, multicentre non-randomised phase II trial (FLUMIZ [FLUdarabine, MItoxantrone, Zevalin] trial) we aimed to assess the efficacy and safety of fludarabine and mitoxantrone plus radioimmunotherapy in untreated patients with follicular non-Hodgkin lymphoma (NHL).",

keywords = "Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Italy, Kaplan-Meier Estimate, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Male, Maximum Tolerated Dose, Middle Aged, Mitoxantrone, Neoplasm Staging, Probability, Radioimmunotherapy, Risk Assessment, Survival Analysis, Vidarabine, Yttrium Radioisotopes, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Italy, Kaplan-Meier Estimate, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Male, Maximum Tolerated Dose, Middle Aged, Mitoxantrone, Neoplasm Staging, Probability, Radioimmunotherapy, Risk Assessment, Survival Analysis, Vidarabine, Yttrium Radioisotopes",

author = "Voso, {Maria Teresa} and FACOLTA', {DI MEDICINA E CHIRURGIA {"}A.GEMELLI{"}} and Pl Zinzani and M Tani and A Pulsoni and M Gobbi and A Perotti and {De Luca}, S and A Fabbri and A Zaccaria and P Fattori and L Guardigni and S Ronconi and Mg Cabras and L Rigacci and {De Renzo}, A and E Marchi and V Stefoni and M Fina and C Pellegrini and G Musuraca and E Derenzini and S Pileri and S Fanti and Pp Piccaluga and M. Baccarani",

year = "2008",

doi = "10.1016/S1470-2045(08)70039-1",

language = "English",

volume = "9",

pages = "352--358",

journal = "THE LANCET ONCOLOGY",

issn = "1470-2045",

publisher = "The Lancet:6277 Sea Harbor:Orlando, FL 32887:(800)462-6198, EMAIL: uslancetcs@elsevier.com, INTERNET: http://www.thelancet.com, Fax: (407)363-1354",

}

Voso, MT, FACOLTA', DIMEDICINAECHIRURGIA, Zinzani, P, Tani, M, Pulsoni, A, Gobbi, M, Perotti, A, De Luca, S, Fabbri, A, Zaccaria, A, Fattori, P, Guardigni, L, Ronconi, S, Cabras, M, Rigacci, L, De Renzo, A, Marchi, E, Stefoni, V, Fina, M, Pellegrini, C, Musuraca, G, Derenzini, E, Pileri, S, Fanti, S, Piccaluga, P & Baccarani, M 2008, 'Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)', THE LANCET ONCOLOGY, vol. 9, pagg. 352-358. https://doi.org/10.1016/S1470-2045(08)70039-1

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). / Voso, Maria Teresa; FACOLTA', DI MEDICINA E CHIRURGIA "A.GEMELLI"; Zinzani, Pl et al.

In: THE LANCET ONCOLOGY, Vol. 9, 2008, pag. 352-358.

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

AU - Voso, Maria Teresa

AU - FACOLTA', DI MEDICINA E CHIRURGIA "A.GEMELLI"

AU - Zinzani, Pl

AU - Tani, M

AU - Pulsoni, A

AU - Gobbi, M

AU - Perotti, A

AU - De Luca, S

AU - Fabbri, A

AU - Zaccaria, A

AU - Fattori, P

AU - Guardigni, L

AU - Ronconi, S

AU - Cabras, Mg

AU - Rigacci, L

AU - De Renzo, A

AU - Marchi, E

AU - Stefoni, V

AU - Fina, M

AU - Pellegrini, C

AU - Musuraca, G

AU - Derenzini, E

AU - Pileri, S

AU - Fanti, S

AU - Piccaluga, Pp

AU - Baccarani, M.

PY - 2008

Y1 - 2008

N2 - Follicular lymphoma is the most common form of lymphoma in Europe and the USA. In this prospective, single-arm, open-labelled, multicentre non-randomised phase II trial (FLUMIZ [FLUdarabine, MItoxantrone, Zevalin] trial) we aimed to assess the efficacy and safety of fludarabine and mitoxantrone plus radioimmunotherapy in untreated patients with follicular non-Hodgkin lymphoma (NHL).

AB - Follicular lymphoma is the most common form of lymphoma in Europe and the USA. In this prospective, single-arm, open-labelled, multicentre non-randomised phase II trial (FLUMIZ [FLUdarabine, MItoxantrone, Zevalin] trial) we aimed to assess the efficacy and safety of fludarabine and mitoxantrone plus radioimmunotherapy in untreated patients with follicular non-Hodgkin lymphoma (NHL).

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Italy

KW - Kaplan-Meier Estimate

KW - Lymphoma, Follicular

KW - Lymphoma, Non-Hodgkin

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Mitoxantrone

KW - Neoplasm Staging

KW - Probability

KW - Radioimmunotherapy

KW - Risk Assessment

KW - Survival Analysis

KW - Vidarabine

KW - Yttrium Radioisotopes

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Italy

KW - Kaplan-Meier Estimate

KW - Lymphoma, Follicular

KW - Lymphoma, Non-Hodgkin

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Mitoxantrone

KW - Neoplasm Staging

KW - Probability

KW - Radioimmunotherapy

KW - Risk Assessment

KW - Survival Analysis

KW - Vidarabine

KW - Yttrium Radioisotopes

UR - http://hdl.handle.net/10807/14558

U2 - 10.1016/S1470-2045(08)70039-1

DO - 10.1016/S1470-2045(08)70039-1

M3 - Article

VL - 9

SP - 352

EP - 358

JO - THE LANCET ONCOLOGY

JF - THE LANCET ONCOLOGY

SN - 1470-2045

ER -

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo